Glutoxim: new about known
https://doi.org/10.17650/3034-2473-2024-1-1-43-51
Abstract
The problem of supportive therapy in oncology is extremely important. At every step of specialized therapy, close attention should be paid to the quality of life of patients during treatment. Any drug used with the goal of improving patient’s quality of life is viewed by the clinicians with interest, especially if it’s a Russia-made drug which has recommended itself as effective for this goal.
About the Authors
L. M. Kogoniya
Department of Oncology and Thoracic Surgery of the Faculty of Advanced Medicine, M.F. Vladimirsky Moscow Regional Clinical Research Institute
Russian Federation
Russian Federation
61/2 Shchepkina St., Moscow 129110,
R. V. Orlova
St. Petersburg City Clinical Oncological Dispensary;
St. Petersburg University
Russian Federation
Russian Federation
3/5 2nd Berezovaya Alley, St. Petersburg 197022; 7/9 Universitetskaya Emb., St. Petersburg 199034
References
1. Smirnov A.I., Kozhemyakin L.A., Levashev Yu.N., Orlov S.V. Sulfur-containing oligopeptides in the treatment of patients with non-small cell lung cancer. Proceedings of the Third Annual Russian Oncological Conference, St. Petersburg, November 29 – December 1, 1999. St. Petersburg, 1999. Pp. 140–141. (In Russ.).
2. Odintsov S.V., Nikolaev A.P., Vinogradova N.N. The experience of using Glutoxim drugs in cancer patients in a medical center. Abstracts of the report on the VIII Russian National Congress “Man and Medicine”, Moscow, April 2–6, 2001. Available at: https://glutoxim.ru/literat/Odincov_Opyt_ispolzovaniya_ preparatov_Glutoksim_u_onkologicheskih_bolnyh_v_ medicinskom_centre.pdf (In Russ.).
3. Sedakova L.A., Mindra N.V., Vasilenko K.P. et al. Preliminary results of the study of the effect of the drug Glutoxim on tumor growth and the effectiveness of polychemotherapy in the experiment. Proceedings of the First All-Russian scientific forum “Innovative technologies of medicine of the XXI century”. Moscow, 2005. Pp. 459–461. (In Russ.).
4. Burova E.B., Vasilenko K.P., Antonov V.G., Nikolsky N.N. Transactivation of the epidermal growth factor receptor with oxidized glutathione and its pharmacological analog Glutoxim in A431 cells. Doklady Akademii nauk = Reports of the Academy of Sciences 2005;404(1):1–3. (In Russ.).
5. Minaeva L.V. Experimental evaluation of the role of changes in the glutathione system in the realization of side cytotoxic effects of repeated administration of cyclophosphane. Dis. ... cand. of Med. Sci. St. Petersburg, 2007. 178 p. (In Russ.).
6. Townsend D.M., Tew K.D. Pharmacology of a mimetic of glutathione disulfide, NOV-002. Biomed Pharmacother 2009;63(2):75–8. DOI: 10.1016/j.biopha.2008.08.019
7. Townsend D.M., He L., Hutchens S. et al. NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance. Cancer Res 2008;68(8):2870 –7. DOI: 10.1158/0008-5472.CAN-07-5957
8. Manikhas G.I., Filatova E.I., Bylinskaya E.N. et al. The use of the drug Glutoxim in combination radiation therapy of locally advanced cervical cancer. Rossiyskiy onkologicheskiy zhurnal = Russian Journal of Oncology 2008;1:23–8. (In Russ.).
9. Vedernikova N.V. The effect of dicarbamine and Glutoxim on the hematological toxicity of antitumor therapy Abstract of dis. ... cand. of Med. Sci. Moscow, 2008. 25 p. (In Russ.).
10. Novelos Therapeutics Inc. Исследования противоопухолевых эффектов препарата NOV-002 на животных и клеточных моделях. Международная конференция по раку EORTC, 2009. Therapeutics Inc. Studies of the antitumor effects of NOV-002 in animals and cell models. Novelos International Cancer Conference EORTC, 2009.
11. Jenderny S., Lin H., Garrett T. et al. Protective effects of a glutathione disulfide mimetic (NOV-002) against cisplatin induced kidney toxicity. Biomed Pharmacother 2010;64(1):73–6. DOI: 10.1016/j.biopha.2009.09.009
12. Filatova E.I., Dyatchina E.V., Bylinskaya E.N. et al. Evaluation of the effectiveness of using the drug Glutoxim during chemoradiation in the treatment of patients with locally advanced cervical cancer uterus. Materials of the All-Russian Scientific and Practical Conference with international participation “Current state of diagnostics, treatment and rehabilitation in gynecological oncology", St. Petersburg, September 2–3, 2010. St. Petersburg, 2010. Pp. 145–147.
13. Bogush T.A., Dudko E.A., Bogush E.A. et al. Glutoxime, as an inhibitor of multiple drug resistance phenotype associated with Pgp expression. Antibiotiki i khimioterpiya = Antibiotics and Chemotherapy 2010;55(5–6):18–23. (In Russ.).
14. Montero A.J., Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011;71(11):1385–96. DOI: 10.2165/11592590-000000000-00000
15. Lyubarsky M.S., Tkachuk O.A., Nimaev V.V. et al. Prevention of in-fectious complications and lymphorrhea in the postoperative period in patients after radical mastectomy. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2011;3(45):40–4. (In Russ.).
16. Montero A.J., Diaz-Montero C.M., Deutsch Y.E. et al. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat 2012;132(1):215–23. DOI: 10.1007/s10549-011-1889-0
17. Diaz-Montero C.M., Wang Y., Shao L. et al. The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoetic and immune suppression byreducing oxidative stress. Free Radic Biol Med 2012;52(9):1560–8.
18. Manikhas G.M., Zhukova N.V. Use of glutoxim in gastric cancer patients receiving platinum-containing chemotherapy. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2012;1(1):44–6. (In Russ.).
19. Shemerovsky A.K. The role of Glutoxim in the chemotherapeutic and surgical treatment of breast cancer. Abstract of dis. ... cand. Med. Sci. St. Petersburg, 2013. 25 p.
20. Gumireddy K., Li A., Cao L. et al. NOV-002 a glutationne disulfide mimetic, suppresses tumor cell invasion and metastasis. J Carcinog Mutagen 2013;2013:S7–002. DOI: 10.4172/2157-2518.S7-002
21. Antushevich A.A., Antonov V.G., Grebenyuk A.N. et al. The pathophysiological basis of the effectiveness of glutoxim as a means of accompanying radiation therapy for oropharyngeal cancer. Vestnik Rossiyskoy voenno-maditsinskoy akademii = Bulletin of the Russian Military Medical Academy 2013;3(43):32–7. (In Russ.).
Review
For citations:
Kogoniya L.M., Orlova R.V. Glutoxim: new about known. Supportive Therapy in Oncology. 2024;1(1):43-51. (In Russ.) https://doi.org/10.17650/3034-2473-2024-1-1-43-51
Views:
273
Email this article 